[go: up one dir, main page]

FI955837A0 - Menetelmä suun kautta annettavan, kiinteän, diklofenaakkia sisältävän annostelumuodon valmistamiseksi - Google Patents

Menetelmä suun kautta annettavan, kiinteän, diklofenaakkia sisältävän annostelumuodon valmistamiseksi

Info

Publication number
FI955837A0
FI955837A0 FI955837A FI955837A FI955837A0 FI 955837 A0 FI955837 A0 FI 955837A0 FI 955837 A FI955837 A FI 955837A FI 955837 A FI955837 A FI 955837A FI 955837 A0 FI955837 A0 FI 955837A0
Authority
FI
Finland
Prior art keywords
dosage form
pct
solid dosage
oral solid
form containing
Prior art date
Application number
FI955837A
Other languages
English (en)
Swedish (sv)
Other versions
FI955837L (fi
FI116039B (fi
Inventor
Peter Heinrich Stahl
Claudio Gamboni
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of FI955837A0 publication Critical patent/FI955837A0/fi
Publication of FI955837L publication Critical patent/FI955837L/fi
Application granted granted Critical
Publication of FI116039B publication Critical patent/FI116039B/fi

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI955837A 1993-06-08 1995-12-04 Menetelmä suun kautta annettavan, kiinteän, diklofenaakkia sisältävän annostelumuodon valmistamiseksi FI116039B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CH171193 1993-06-08
CH171193 1993-06-08
PCT/EP1994/001662 WO1994028936A1 (en) 1993-06-08 1994-05-24 Process for the preparation of an oral solid dosage form containing diclofenac
EP9401662 1994-05-24

Publications (3)

Publication Number Publication Date
FI955837A0 true FI955837A0 (fi) 1995-12-04
FI955837L FI955837L (fi) 1995-12-04
FI116039B FI116039B (fi) 2005-09-15

Family

ID=4216820

Family Applications (1)

Application Number Title Priority Date Filing Date
FI955837A FI116039B (fi) 1993-06-08 1995-12-04 Menetelmä suun kautta annettavan, kiinteän, diklofenaakkia sisältävän annostelumuodon valmistamiseksi

Country Status (14)

Country Link
US (1) US5702724A (fi)
EP (1) EP0701449B1 (fi)
JP (2) JPH08511009A (fi)
AT (1) ATE246515T1 (fi)
AU (1) AU6971294A (fi)
CA (1) CA2163111C (fi)
DE (1) DE69433012T2 (fi)
DK (1) DK0701449T3 (fi)
ES (1) ES2204918T3 (fi)
FI (1) FI116039B (fi)
NO (1) NO315844B1 (fi)
NZ (1) NZ267417A (fi)
PT (1) PT701449E (fi)
WO (1) WO1994028936A1 (fi)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4353996A (en) * 1994-12-14 1996-07-03 Bioglan Ireland (R & D) Limited Pharmaceutical tablet formulations for direct compression
HUP9600758A2 (en) * 1996-03-27 1998-03-02 Cyclolab Ciklodextrin Kutato F Diclofenac composition of diminished gastrointestinal irritation and enhanced biological resorption
US6720005B1 (en) * 2000-07-07 2004-04-13 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Coated, platform-generating tablet
PE20020351A1 (es) * 2000-09-11 2002-06-14 Novartis Ag Composiciones farmaceuticas que comprenden acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico como inhibidor de la ciclooxigenasa-2
AR036312A1 (es) * 2001-08-31 2004-08-25 Novartis Ag Composicion farmaceutica
JP2005298338A (ja) * 2002-02-27 2005-10-27 Eisai Co Ltd 速崩壊性圧縮成形製剤
AR038747A1 (es) * 2002-03-07 2005-01-26 Novartis Ag Una composicion farmaceutica solida para tratar un desorden o condicion dependiente de la ciclooxigenasa-2
US20040241234A1 (en) * 2003-06-02 2004-12-02 Alpharma, Inc. Controlled release press-coated formulations of water-soluble active agents
EP1707217A1 (en) * 2004-12-17 2006-10-04 Wacker Chemie AG Process for preparing an alpha lipoic acid/cyclodextrin complex and product prepared
DE102004060914A1 (de) * 2004-12-17 2006-07-06 Bioghurt Biogarde Gmbh & Co. Kg Verwendung von Liponsäure-haltigen Cyclodextrin-Komplexen
BRPI0709409A2 (pt) 2006-03-28 2011-07-12 Javelin Pharmaceuticals Inc composição farmacêutica e método para tratar um mamìfero necessitando de analgesia
EP2003970A4 (en) * 2006-03-28 2012-07-11 Javelin Pharmaceuticals Inc FORMULATIONS OF LOW-DOSEED NON-STEROID INFLAMMATORY INHIBITORS AND BETA-CYCLODEXTRIN
US20110144207A1 (en) * 2008-08-14 2011-06-16 Shasun Chemicals And Drugs Limited Aryl alkyl carboxylic acid salts, process for preparation and dosage forms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5959632A (ja) * 1982-09-28 1984-04-05 Teikoku Chem Ind Corp Ltd 徐放性組成物
JPS5984821A (ja) * 1982-11-04 1984-05-16 Teikoku Chem Ind Corp Ltd 徐溶化組成物
FR2660195B1 (fr) * 1990-03-28 1994-10-07 Crinex Sa Laboratoires Composition pharmaceutique a macher, antiinflammatoire et/ou analgesique.
IT1243342B (it) * 1990-07-13 1994-06-10 Farcon Ag Composizioni farmaceutiche orali liquide ad attivita' antiinfiammatoria
DE69013689T2 (de) * 1990-11-29 1995-03-02 Wei Ming Pharmaceutical Mfg Co Hilfsträger für direkte Verpressung.
US5231089A (en) * 1991-12-02 1993-07-27 University Of Florida Method of improving oral bioavailability of carbamazepine

Also Published As

Publication number Publication date
NO954952D0 (no) 1995-12-06
PT701449E (pt) 2003-12-31
WO1994028936A1 (en) 1994-12-22
NO315844B1 (no) 2003-11-03
ATE246515T1 (de) 2003-08-15
AU6971294A (en) 1995-01-03
FI955837L (fi) 1995-12-04
JP2005247874A (ja) 2005-09-15
EP0701449A1 (en) 1996-03-20
DK0701449T3 (da) 2003-11-10
DE69433012D1 (de) 2003-09-11
ES2204918T3 (es) 2004-05-01
JPH08511009A (ja) 1996-11-19
CA2163111C (en) 2010-10-26
NZ267417A (en) 1997-02-24
NO954952L (no) 1995-12-06
FI116039B (fi) 2005-09-15
DE69433012T2 (de) 2004-06-09
CA2163111A1 (en) 1994-12-22
EP0701449B1 (en) 2003-08-06
US5702724A (en) 1997-12-30

Similar Documents

Publication Publication Date Title
TR27835A (tr) Sübstitüe edilmis azadiokzasikloalkenler.
ZA948670B (en) New benzoyl guanidine derivatives,the preparation thereof and their use in pharmaceutical compositions
WO1990009993A3 (en) Method for the synthesis of huperzine a and analogs thereof and compounds useful therein
FI955837A0 (fi) Menetelmä suun kautta annettavan, kiinteän, diklofenaakkia sisältävän annostelumuodon valmistamiseksi
FI972434A0 (fi) Lamotrigiiniä sisältävä farmaseuttinen koostumus
ZA952614B (en) The use of carboxylic acid derivatives as drugs
HU9303000D0 (en) Aryl-morpholine-derivatives and pharmaceutical compositions containing it and process for production thereof
GR890100833A (en) Process for the preparation of a compound with gastric inhibitopy effect
DK0866711T3 (da) Anvendelse af 6-methyl-5-oxo-3-thiomorpholinylcarbonyl-L-histidyl-L-prolinamid til fremstilling af et farmaceutisk præparat til modvirkning af sövnapnö
NZ332545A (fi)
TW261605B (fi)
BR9610175A (pt) Composto processo de preparação do composto composição farmacêutica e utilização do composto
GEP20043377B (en) Pharmaceutical Complex
AU675281B2 (en) Application of riluzole as a radiorestorer
HUT68015A (en) New compound leustroducsin h, its preparation and pharmaceutical compositions containing them
SE9304065D0 (sv) New compound

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: NOVARTIS AG

FG Patent granted

Ref document number: 116039

Country of ref document: FI

MA Patent expired